Advanced Liver Cancer Clinical Trial
Official title:
Clinical Study Using Precision Cell Immunotherapy Combination With Transcatheter Arterial Chemoembolization in Advanced Liver Cancer
To evaluate the safety and effectiveness of cell therapy using precision cells Combined With
TACE in Advanced Liver Cancer.
Eligibility:
Individuals greater than or equal to 18 years of age and less than or equal to 65 years of
age who have been diagnosed with Advanced Liver Cancer.
A total of 40 patients may be enrolled over a period of 1-2 years. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01754987 -
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05698459 -
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients With Advanced Liver Cancer
|
Phase 1 | |
| Recruiting |
NCT03146637 -
Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer
|
Phase 2 | |
| Withdrawn |
NCT03484962 -
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer
|
Phase 2 | |
| Recruiting |
NCT05603039 -
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04906434 -
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
|
Phase 1 | |
| Recruiting |
NCT04163237 -
Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer
|
Phase 3 | |
| Recruiting |
NCT02862613 -
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03474822 -
Plasmodium Immunotherapy for Breast and Liver Cancers
|
Phase 1/Phase 2 |